Of the IA patients, KRAS mutations were most frequent in acinar-predominant (5.63%), followed by solid-predominant adenocarcinoma (4.76%), lepidic-predominant (2.70%), and papillary-predominant carcinoma (0.00%) (Figure 2C). Here, KRAS is linked to adenocarcinoma.